



JAGSONPAL PHARMACEUTICALS LTD.

CIN: L74899DL1978PLC009181

Registered Office: T-210 J, Shahpur Jat, New Delhi – 110049

Phone No.: 011-46181100, Email: cs@jagsonpal.com, website: jagsonpal.com

April 10, 2023

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---	--

Dear Sir/ Madam,

Subject: Disclosures under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

In terms of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 we are hereby enclosing the Annual disclosures of our promoters under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the year ended on March 31, 2023 for compliance.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For **Jagsonpal Pharmaceuticals Limited**

**ABHISHEK
JOSHI**

Digitally signed by ABHISHEK JOSHI
DN: cn=ABHISHEK JOSHI c=IN
l=JODHPUR o=Personal
e=ABHISHEKJOSHI50@GMAIL.COM
Reason: E-form Filing
Location:
Date: 2023-04-10 10:24+05:30

Abhishek Joshi
Company Secretary & Compliance Officer

Encl: as above

**Corporate Office: Nimai Tower, 3rd Floor, Plot No.: 412-415, Udyog Vihar Phase - IV, Gurgaon,
Haryana – 122015, Phone No.:0124-4406710**

Infinity Holdings

C/o Apex Fund & Corporate Services (Mauritius) Ltd,
Lot 15 A3, 1st Floor, Cybercity, Ebene 72201, Mauritius
Tel: +230 404 3900 Fax: +230 454 6824

April 6th 2023

The Manager BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Manager National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---	--

Sub: Disclosure by Promoters of Listed Company under Regulation 31 (4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir/Madam,

Pursuant to the provisions of Regulation 31 (4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, We, Infinity Holdings along with persons acting with concert of Jagsonpal Pharmaceuticals Limited, hereby declare that we have not made any encumbrance of shares, directly or indirectly during the financial year ended March 31th 2023.

Kindly take the above-mentioned information on your record.

For Infinity Holdings



Encl: as above

CC:

Infinity Holdings Sidecar I
Infinity Consumer Holdings

CC:

The Audit Committee
Jagsonpal Pharmaceuticals Limited
T-210 J, Shahpur Jat,
New Delhi-110049

CC:

The Company Secretary,
Jagsonpal Pharmaceuticals Limited
T-210 J, Shahpur Jat,
New Delhi-110049

April 09, 2023

The Manager BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Manager National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---	--

Sub: Disclosure by Promoters of Listed Company under Regulation 31 (4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Dear Sir & Madam,

Pursuant to the provisions of Regulation 31 (4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we, **Rajpal Singh Kochhar** and **Aresko Progressive Private Limited**, Promoter of Jagsonpal Pharmaceuticals Limited, hereby declare that we, including Persons acting in concert have not made any encumbrance of shares, directly or indirectly during the financial year ended March 31, 2023.

Kindly take the above-mentioned information on your record.

For and on behalf of Aresko Progressive Private Limited



Rajpal Singh Kochhar

Encl: as above.

CC: The Audit Committee
Jagsonpal Pharmaceuticals Limited
T-210 J, Shahpur Jat,
New Delhi-110049

CC: The Company Secretary,
Jagsonpal Pharmaceuticals Limited
T-210 J, Shahpur Jat,
New Delhi-110049